Cargando…

Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review

Since angiotensin increases the expression of plasminogen activator inhibitor (PAI), mechanisms associated with an actively functioning renin–angiotensin–aldosterone system can be expected to be associated with increased PAI-1 expression. These mechanisms are present not only in common conditions re...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Elia, John A., Bayliss, George, Gleason, Ray E., Weinrauch, Larry A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036907/
https://www.ncbi.nlm.nih.gov/pubmed/27679717
http://dx.doi.org/10.1093/ckj/sfw080
_version_ 1782455647205326848
author D'Elia, John A.
Bayliss, George
Gleason, Ray E.
Weinrauch, Larry A.
author_facet D'Elia, John A.
Bayliss, George
Gleason, Ray E.
Weinrauch, Larry A.
author_sort D'Elia, John A.
collection PubMed
description Since angiotensin increases the expression of plasminogen activator inhibitor (PAI), mechanisms associated with an actively functioning renin–angiotensin–aldosterone system can be expected to be associated with increased PAI-1 expression. These mechanisms are present not only in common conditions resulting in glomerulosclerosis associated with aging, diabetes or genetic mutations, but also in autoimmune disease (like scleroderma and lupus), radiation injury, cyclosporine toxicity, allograft nephropathy and ureteral obstruction. While the renin–angiotensin–aldosterone system and growth factors, such as transforming growth factor-beta (TGF-β), are almost always part of the process, there are rare experimental observations of PAI-1 expression without their interaction. Here we review the literature on PAI-1 and its role in vascular, fibrotic and oxidative injury as well as work suggesting potential areas of intervention in the pathogenesis of multiple disorders.
format Online
Article
Text
id pubmed-5036907
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-50369072016-09-27 Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review D'Elia, John A. Bayliss, George Gleason, Ray E. Weinrauch, Larry A. Clin Kidney J Cardiovascular Disease and CKD Since angiotensin increases the expression of plasminogen activator inhibitor (PAI), mechanisms associated with an actively functioning renin–angiotensin–aldosterone system can be expected to be associated with increased PAI-1 expression. These mechanisms are present not only in common conditions resulting in glomerulosclerosis associated with aging, diabetes or genetic mutations, but also in autoimmune disease (like scleroderma and lupus), radiation injury, cyclosporine toxicity, allograft nephropathy and ureteral obstruction. While the renin–angiotensin–aldosterone system and growth factors, such as transforming growth factor-beta (TGF-β), are almost always part of the process, there are rare experimental observations of PAI-1 expression without their interaction. Here we review the literature on PAI-1 and its role in vascular, fibrotic and oxidative injury as well as work suggesting potential areas of intervention in the pathogenesis of multiple disorders. Oxford University Press 2016-10 2016-08-31 /pmc/articles/PMC5036907/ /pubmed/27679717 http://dx.doi.org/10.1093/ckj/sfw080 Text en © The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Cardiovascular Disease and CKD
D'Elia, John A.
Bayliss, George
Gleason, Ray E.
Weinrauch, Larry A.
Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review
title Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review
title_full Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review
title_fullStr Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review
title_full_unstemmed Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review
title_short Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review
title_sort cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review
topic Cardiovascular Disease and CKD
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036907/
https://www.ncbi.nlm.nih.gov/pubmed/27679717
http://dx.doi.org/10.1093/ckj/sfw080
work_keys_str_mv AT deliajohna cardiovascularrenalcomplicationsandthepossibleroleofplasminogenactivatorinhibitorareview
AT baylissgeorge cardiovascularrenalcomplicationsandthepossibleroleofplasminogenactivatorinhibitorareview
AT gleasonraye cardiovascularrenalcomplicationsandthepossibleroleofplasminogenactivatorinhibitorareview
AT weinrauchlarrya cardiovascularrenalcomplicationsandthepossibleroleofplasminogenactivatorinhibitorareview